eyonis® HCC (Liver Cancer)
AI-driven diagnostic solution for hepatocellular carcinoma management
Software · Cloud SaaSCompany source
Company profile
About Median Technologies
Median Technologies is a medical imaging company that deploys proprietary artificial intelligence, computer vision, and signal processing technologies to develop imaging tests and services addressing life-threatening unmet medical needs. The company operates two main business lines: iCRO, which provides state-of-the-art medical image management and oncology clinical trial imaging services for pharmaceutical, biotech, and CRO partners globally; and eyonis®, an AI/ML Software as Medical Device (SaMD) platform currently under development for precision diagnostics in lung cancer screening and liver cancer (HCC). Through its Imaging Lab offering, Median delivers AI-powered insights and imaging biomarker discovery to accelerate drug development. The company transforms medical images into meaningful, actionable insights throughout the entire patient journey, from early-stage patient selection and predictive biomarker discovery to companion diagnostics development and routine clinical diagnosis. Median's iSee Platform and end-to-end quality processes help life sciences companies extract drug efficacy data and streamline clinical trials. The company recently received FDA 510(k) clearance for eyonis® LCS, described as the first AI tech-based detection and diagnosis device for lung cancer screening. Median Technologies is listed on Euronext Growth and serves a global customer base with major shareholders from Europe, USA, and Asia.
Company description Median Technologies official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceLinkedIn
Work at Median Technologies?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Liver cancer (HCC)
- Lung cancer
- Oncology (general)
Who it serves
- Biotechnology companies
- Clinical Research Organizations (CROs)
- Healthcare professionals
- Pharmaceutical companies
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsAsia · Europe · Global · USA
Company sourceOfficial website
Company milestones
Platform expansion
FDA 510(k) clearance for eyonis® LCS received (first AI tech-based detection and diagnosis device for lung cancer screening). Collaboration with Tempus announced to expand eyonis® LCS access in United States. Capital increase successfully completed June 2026. Exhibiting at ASCO 2026 Annual Meeting.
Partnerships
Recorded partners
- Tempus (collaboration announced for eyonis® LCS expansion in United States)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
eyonis® LCS (Lung Cancer Screening)
FDA-cleared AI-based detection and diagnosis device for lung cancer screening
Software · Cloud SaaSCompany source
iCRO - Imaging Services for Oncology Clinical Trials
End-to-end image management and AI-powered insights for oncology clinical trials
Service · Cloud SaaSCompany source
Imaging Lab
AI-powered imaging intelligence for actionable drug development insights
Platform · Cloud SaaSCompany source
iSee Platform
Operational platform for oncology clinical trial imaging management
Platform · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
What are RECIST 1.1 progressions made of? Variability in double-read oncology trials.European radiology · Jul 1, 2026
Large language models in neuro-oncology: promise, pitfalls, and the path forward.European radiology · Jun 1, 2026
Technical performance of L3 skeletal muscle area (SMA) measurement on CT for L3 skeletal muscle index (L3SMI) assessment.Scientific reports · May 12, 2026
Radiomics-Based Prediction of Treatment Response to TRuC-T Cell Therapy in Patients with Mesothelioma: A Pilot Study.Cancers · Jan 29, 2025
RECIST 1.1 assessments variability: a systematic pictorial review of blinded double reads.Insights into imaging · Aug 7, 2024
Evaluation of digital medical devices: How to take into account the specificities of these solutions?Therapie · Jan 1, 2024
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
Median LCS (internal name) / eyonis LCS (trade name) (1.0)K251474 · 510k · Feb 6, 2026
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Early diagnosis
Helping diagnose patients earlier through AI-powered imaging analysis
Drug development acceleration
Streamlining clinical trial processes and extracting drug efficacy data
Imaging biomarker discovery
Predictive imaging biomarkers for patient selection and companion diagnostics
Tempus
Collaboration to expand access to eyonis® LCS Software as a Medical Device in the United States
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Median Technologies
Recent articles published on Median Technologies's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.